Author

Hirotake Kasai

University of Yamanashi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:rat· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Atsuya Yamashita· 4 shared Kohji MoriishiiD· 4 shared Tomohisa TanakaiD· 3 shared Yasunori Akaike· 3 shared Yoshiharu MatsuuraiD· 3 shared Atsushi Miyajima· 1 shared Haruyo Aoyagi· 1 shared Hideki AizakiiD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

Atsuya Yamashita

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Vorapaxar and aripiprazole suppress hepatitis B virus replication through distinct host signaling pathways

Atsuya Yamashita, Hirotake Kasai, Haruyo Aoyagi, Kousho Wakae, Kaoru Kobayashi, Atsushi Miyajima, Yuichiro Higuchi, Hiroshi Suemizu, Ryo Fukushima, Masanori Isogawa, Takaji Wakita, Hideki Aizaki, Kohji Moriishi

This paper identifies vorapaxar and aripiprazole as inhibitors of HBV replication through distinct host signaling pathways, showing their potential as host-targeting antivirals.

bioRxiv · Aug 9, 2026 · PreprintPharmacology & Toxicology

Generation of a HiBiT-expressing recombinant rat hepacivirus supporting both in vivo and in vitro infection

Yasunori Akaike, Tomohisa Tanaka, Hirotake Kasai, Atsuya Yamashita, Yoshiharu Matsuura, Kohji Moriishi

This paper develops a HiBiT-expressing recombinant rat hepacivirus that can infect both in vitro and in vivo, enabling quantitative antiviral screening and pathogenicity studies.

PLoS Pathogens · Apr 8, 2026Peer-reviewedMicrobiology

Identification of claudin-3 as an entry factor for rat hepacivirus

Tomohisa Tanaka, Yasunori Akaike, Hirotake Kasai, Atsuya Yamashita, Yoshiharu Matsuura, Kohji Moriishi

This study identifies claudin-3 as an entry factor for rat hepacivirus, showing host-specificity determined by two amino acids in extracellular loop 1.

Proceedings of the National Academy of Sciences · Oct 2, 2025Peer-reviewedMicrobiology

HCV infection activates the proteasome via PA28γ acetylation and heptamerization to facilitate the degradation of RNF2, a catalytic component of polycomb repressive complex 1.

Hirotake Kasai, Atsuya Yamashita, Yasunori Akaike, Tomohisa Tanaka, Yoshiharu Matsuura, Kohji Moriishi

This study identifies that HCV infection promotes PA28γ acetylation and heptamerization, enhancing proteasomal degradation of RNF2 and leading to HOX gene expression.

mBio · Sep 27, 2024Peer-reviewedMicrobiology